Evotec Announces Progress in Strategic Neuroscience Partnership With Bristol Myers Squibb

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.

Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression. The progress announced here leverages Evotec’s PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.

The partnership has generated a promising pipeline of discovery to clinical-stage programmes. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. In March 2023, Bristol Myers Squibb and Evotec extended and expanded their partnership for an additional 8 years.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “The achieved milestone underlines the productive nature of our neuroscience partnership with Bristol Myers Squibb. Using our PanOmics-driven drug discovery platform we are targeting neurodegenerative diseases with tremendous unmet medical need. Beyond BMS-986419, we are very excited to advance yet another programme towards the clinic development in 2026.”